BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 33110482)

  • 21. Correction: MR imaging biomarkers evaluating vascular normalization window after anti-vessel treatment.
    Yang J; Liao C; Liu Y; Yang G; Ke T; Ding Y; Li Q
    Oncotarget; 2022; 13():641. PubMed ID: 35548328
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Correction: HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer.
    Hideshima T; Mazitschek R; Qi J; Mimura N; Tseng JC; Kung AL; Bradner JE; Anderson KC
    Oncotarget; 2021 Aug; 12(17):1736. PubMed ID: 34434504
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Correction: Targeting a ribonucleoprotein complex containing the caprin-1 protein and the c-Myc mRNA suppresses tumor growth in mice: an identification of a novel oncotarget.
    Qiu YQ; Yang CW; Lee YZ; Yang RB; Lee CH; Hsu HY; Chang CC; Lee SJ
    Oncotarget; 2019 Aug; 10(47):4919. PubMed ID: 31448057
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Correction: Inhibitor SBFI26 suppresses the malignant progression of castration-resistant PC3-M cells by competitively binding to oncogenic FABP5.
    Al-Jameel W; Gou X; Forootan SS; Fayi MSA; Rudland PS; Forootan FS; Zhang J; Cornford PA; Hussain SA; Ke Y
    Oncotarget; 2020 Aug; 11(31):3025. PubMed ID: 32821347
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Correction: First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL.
    Byrd JC; Smith S; Wagner-Johnston N; Sharman J; Chen AI; Advani R; Augustson B; Marlton P; Commerford SR; Okrah K; Liu L; Murray E; Penuel E; Ward AF; Flinn IW
    Oncotarget; 2019 Jun; 10(38):3827-3830. PubMed ID: 31217910
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preclinical efficacy of maternal embryonic leucine-zipper kinase (MELK) inhibition in acute myeloid leukemia.
    Alachkar H; Mutonga MB; Metzeler KH; Fulton N; Malnassy G; Herold T; Spiekermann K; Bohlander SK; Hiddemann W; Matsuo Y; Stock W; Nakamura Y
    Oncotarget; 2014 Dec; 5(23):12371-82. PubMed ID: 25365263
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Correction:
    Contis-Montes de Oca A; Rodarte-Valle E; Rosales-Hernández MC; Abarca-Rojano E; Rojas-Hernández S; Fragoso-Vázquez MJ; Mendieta-Wejebe JE; Correa-Basurto AM; Vázquez-Moctezuma I; Correa-Basurto J
    Oncotarget; 2019 Feb; 10(11):1225. PubMed ID: 30838095
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Correction: The Nrf2 inhibitor brusatol is a potent antitumour agent in an orthotopic mouse model of colorectal cancer.
    Evans JP; Winiarski BK; Sutton PA; Jones RP; Ressel L; Duckworth CA; Pritchard DM; Lin ZX; Fretwell VL; Tweedle EM; Costello E; Goldring CE; Copple IM; Park BK; Palmer DH; Kitteringham NR
    Oncotarget; 2019 Jan; 10(6):685. PubMed ID: 30774766
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Erratum: Publisher Correction to: Multiple articles in Food Science and Biotechnology.
    Publisher
    Food Sci Biotechnol; 2018 Aug; 27(4):1245. PubMed ID: 30265261
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Correction: PD-L1 expression heterogeneity in non-small cell lung cancer: evaluation of small biopsies reliability.
    Munari E; Zamboni G; Marconi M; Sommaggio M; Brunelli M; Martignoni G; Netto GJ; Moretta F; Mingari MC; Salgarello M; Terzi A; Picece V; Pomari C; Lunardi G; Cavazza A; Rossi G; Moretta L; Bogina G
    Oncotarget; 2018 Dec; 9(97):37077. PubMed ID: 30651938
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Correction: Evaluation of tenascin-C by tenatumomab in T-cell non-Hodgkin lymphomas identifies a new target for radioimmunotherapy.
    Gritt G; Gianatt A; Petronzeii F; De Santis R; Pavoni C; Rossi RL; Cattaneo L; Spagnoli LG; Ferrar S; Ross A; Barbu AM; Rambald A
    Oncotarget; 2018 Mar; 9(24):17256. PubMed ID: 29683132
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Erratum: Publisher Correction: articles initially published in wrong volume.
    Cell Death Discov; 2019; 5():116. PubMed ID: 31312525
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effective growth-suppressive activity of maternal embryonic leucine-zipper kinase (MELK) inhibitor against small cell lung cancer.
    Inoue H; Kato T; Olugbile S; Tamura K; Chung S; Miyamoto T; Matsuo Y; Salgia R; Nakamura Y; Park JH
    Oncotarget; 2016 Mar; 7(12):13621-33. PubMed ID: 26871945
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Correction: Colon cancer-induced interleukin-35 inhibits betacatenin- mediated pro-oncogenic activity.
    Jiang Y; Ma Y; Li R; Sun J
    Oncotarget; 2018 Aug; 9(60):31788. PubMed ID: 30167095
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MELK is not necessary for the proliferation of basal-like breast cancer cells.
    Huang HT; Seo HS; Zhang T; Wang Y; Jiang B; Li Q; Buckley DL; Nabet B; Roberts JM; Paulk J; Dastjerdi S; Winter GE; McLauchlan H; Moran J; Bradner JE; Eck MJ; Dhe-Paganon S; Zhao JJ; Gray NS
    Elife; 2017 Sep; 6():. PubMed ID: 28926338
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Correction: P-cadherin mutations are associated with high basal Wnt activity and stemness in canine mammary tumor cell lines.
    Timmermans-Sprang E; Collin RWJ; Henkes A; Philipsen M; Mol JA
    Oncotarget; 2020 Feb; 11(5):573. PubMed ID: 32082491
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sanguinarine triggers intrinsic apoptosis to suppress colorectal cancer growth through disassociation between STRAP and MELK.
    Gong X; Chen Z; Han Q; Chen C; Jing L; Liu Y; Zhao L; Yao X; Sun X
    BMC Cancer; 2018 May; 18(1):578. PubMed ID: 29783958
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Correction: HDAC inhibitors enhance neratinib activity and when combined enhance the actions of an anti-PD-1 immunomodulatory antibody
    Booth L; Roberts JL; Poklepovic A; Avogadri-Connors F; Cutler RE; Lalani AS; Dent P
    Oncotarget; 2019 Aug; 10(49):5120-5122. PubMed ID: 31489122
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Correction: Aryl hydrocarbon receptor regulates histone deacetylase 8 expression to repress tumor suppressive activity in hepatocellular carcinoma.
    Wang LT; Chiou SS; Chai CY; Hsi E; Wang SN; Huang SK; Hsu SH
    Oncotarget; 2018 Dec; 9(102):37807. PubMed ID: 30701034
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Correction:
    Guo W; Xu P; Jin T; Wang J; Fan D; Hao Z; Ji Y; Jing S; Han C; Du J; Jiang D; Wen S; Wang J
    Oncotarget; 2018 Apr; 9(28):20221. PubMed ID: 29733083
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.